This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Deborah J. Moritz, PhD; Patrick J. Fox, PhD; Faye A. Luscombe, DrPH; Helena C. Kraemer, PhD

Arch Neurol. 1997;54(7):878-885.

Abstract
Objective
To determine whether neurological and psychiatric symptoms predict survival time among patients with Alzheimer disease (AD) after adjusting for the influence of sociodemographic variables, health conditions, and dementia severity separately for men and women.

Design
The sample consisted of 936 men and women diagnosed as having probable or possible AD at 1 of 7 Alzheimer's Disease Diagnostic and Treatment Centers throughout California from 1986 through 1990. Data on dementia severity, comorbid conditions, and demographic characteristics were collected at the time of AD diagnosis. Data on vital status and dates of death were obtained by linking the patient file to several administrative databases maintained by the California State and federal governments. The mean length of follow-up was 31 months. Data were analyzed with Kaplan-Meier survival curves and Cox proportional hazards models.

Results
Men had shorter survival times than did women (log-rank test, 30.93, P<.001). Among men, but not women, survival times were negatively associated with selected neurological and psychiatric symptoms. Among women, but not men, a history of cardiovascular conditions was associated with poorer survival.

Conclusions
Patterns of survival and predictors of survival time among patients with AD differ by sex. Future studies of survival and progression of AD need to examine men and women separately.

Author Affiliations
From the Department of Epidemiology and Biostatistics (Dr Moritz), and Institute for Health and Aging and Department of Social and Behavioral Sciences (Dr Fox), University of California, San Francisco; Parke-Davis Pharmaceutical Research Division, Warner-Lambert Co, Ann Arbor, Mich (Dr Luscombe); and Departments of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, Calif (Dr Kraemer). Dr Luscombe is now in private practice in Richland, Mich.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Galantamine for the Treatment of BPSD in Thai Patients With Possible Alzheimer's Disease With or Without Cerebrovascular Disease
Tangwongchai et al.
AM J ALZHEIMERS DIS OTHER DEMEN 2009;23:593-601.
ABSTRACT  

Disruptive Behavior as a Predictor in Alzheimer Disease
Scarmeas et al.
Arch Neurol 2007;64:1755-1761.
ABSTRACT | FULL TEXT  

Mediterranean diet and Alzheimer disease mortality
Scarmeas et al.
Neurology 2007;69:1084-1093.
ABSTRACT | FULL TEXT  

Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine.
Lopez-Pousa et al.
Age Ageing 2006;35:365-371.
ABSTRACT | FULL TEXT  

Prevalence and clinical correlates of neuropsychiatric symptoms in dementia
Steffens et al.
AM J ALZHEIMERS DIS OTHER DEMEN 2005;20:367-373.
ABSTRACT  

Delusions and Hallucinations Are Associated With Worse Outcome in Alzheimer Disease
Scarmeas et al.
Arch Neurol 2005;62:1601-1608.
ABSTRACT | FULL TEXT  

Motor signs predict poor outcomes in Alzheimer disease
Scarmeas et al.
Neurology 2005;64:1696-1703.
ABSTRACT | FULL TEXT  

Alzheimer Disease and Mortality: A 15-Year Epidemiological Study
Ganguli et al.
Arch Neurol 2005;62:779-784.
ABSTRACT | FULL TEXT  

Medial Temporal Hypoperfusion and Aggression in Alzheimer Disease
Lanctot et al.
Arch Neurol 2004;61:1731-1737.
ABSTRACT | FULL TEXT  

Estimating Prognosis for Nursing Home Residents With Advanced Dementia
Alvarez-Fernandez
JAMA 2004;292:1553-1553.
FULL TEXT  

Rate of cognitive decline and mortality in Alzheimer's disease
Hui et al.
Neurology 2003;61:1356-1361.
ABSTRACT | FULL TEXT  

Health Care Utilization in Dementia Patients With Psychiatric Comorbidity
Kunik et al.
Gerontologist 2003;43:86-91.
ABSTRACT | FULL TEXT  

Functional Transitions and Active Life Expectancy Associated With Alzheimer Disease
Dodge et al.
Arch Neurol 2003;60:253-259.
ABSTRACT | FULL TEXT  

Rates of progression in mild cognitive impairment and early Alzheimer's disease
Storandt et al.
Neurology 2002;59:1034-1041.
ABSTRACT | FULL TEXT  

APOE genotype and survival in men and women with Alzheimer's disease
Dal Forno et al.
Neurology 2002;58:1045-1050.
ABSTRACT | FULL TEXT  

Predictor Index of Mortality in Dementia Patients Upon Entry Into Long-term Care
Carlson et al.
Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2001;56:M567-570.
ABSTRACT | FULL TEXT  

Gender differences in predictors of mortality in nursing home residents with AD
Lapane et al.
Neurology 2001;56:650-654.
ABSTRACT | FULL TEXT  

Psychiatric Medication and Abnormal Behavior as Predictors of Progression in Probable Alzheimer Disease
Lopez et al.
Arch Neurol 1999;56:1266-1272.
ABSTRACT | FULL TEXT  

Gender differences in the relation between comorbidity and mortality of patients with Alzheimer's disease
Gambassi et al.
Neurology 1999;53:508-508.
ABSTRACT | FULL TEXT  

Predictors of mortality in patients with Alzheimer's disease living in nursing homes
Gambassi et al.
J. Neurol. Neurosurg. Psychiatry 1999;67:59-65.
ABSTRACT | FULL TEXT  

Women and Alzheimer's Disease
Lerner
J. Clin. Endocrinol. Metab. 1999;84:1830-1834.
FULL TEXT